Restructuring and Sale Considerations After Clinical Failure: Attention on Bio Company with $400 Million Cash

Theravance Biopharma, Inc. (Nasdaq: TBPH) reported its fourth‐quarter and full‐year 2025 results on March 19, announcing a record non‐GAAP profit driven by milestone payments from YUPELRI and TRELEGY. In response to the Phase 3 CYPRESS study setback, the company is restructuring its R&D organization, cutting approximately 50 percent of its workforce and reducing operating expenses by about 60 percent. Theravance now aims to generate annual cash flow of $60–70 million beginning in the third quarter of 2026.

As of the end of the first quarter of 2026, Theravance expects to hold roughly $400 million in cash and cash equivalents and to remain debt-free. An independent Strategic Review Committee, established by the board of directors, is accelerating its review of strategic alternatives, including a potential sale of the company.

Following the announcement of the CYPRESS results and a roughly 26 percent drop in share price, U.S. law firm Levi & Korsinsky LLP notified Theravance Biopharma shareholders of its intent to evaluate participation in a securities class action. The firm alleges that the company’s disclosures regarding the clinical failure and its financial guidance were deficient.

Theravance Biopharma, headquartered in Dublin and listed on Nasdaq, specializes in respiratory diseases with a focus on its chronic obstructive pulmonary disease treatment YUPELRI. The company had been developing ampreloxetine for neurogenic orthostatic hypotension but recently discontinued the program after clinical setbacks. Theravance is now concentrating on cash generation from its commercial portfolio, including YUPELRI sales and milestone revenues from TRELEGY under its agreement with Royalty Pharma.